Companies: 10,795·Total market cap: $144.5T
ARYx Therapeutics, Inc.

ARYx Therapeutics, Inc.

ARYXOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$16731
P/E Ratio
52W High$0.00050000002
52W Low$0.000001
Overview

ARYx Therapeutics, Inc. (ARYX) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

ARYX · shares outstanding · updated Jun 10, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
27.4M +44.68% YoY Change
FY · as of Dec 31, 2009 · Reported in USD
vs 19.0M in FY 2008
Diluted Shares Outstanding
27.4M
incl. options, RSUs, convertibles
Dilution Spread
+0.00%
Diluted vs Basic
YoY Change
+44.68%
year-over-year
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-10

Shares Outstanding Growth Rate

3-Year CAGRincreasing
+199.8%
2006 → 2009
5-Year CAGRincreasing
+100.0%
2004 → 2009
10-Year CAGR

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2009Latest
Diluted Shares: 27.4M
27.4M
+44.68%
FY 2008
Diluted Shares: 19.0M
19.0M
+101.62%
FY 2007
Diluted Shares: 9.4M
9.4M
+823.95%
FY 2006
Diluted Shares: 1.0M
1.0M
+11.87%
FY 2005
Diluted Shares: 910,000
910,000
+6.06%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs ARYX
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+>999%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+>999%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+>999%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+>999%
#5
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M+>999%
#6
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M+>999%
#7
ARYx Therapeutics, Inc.ARYX
ARYx Therapeutics, Inc.YOU
27.4M

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

ARYx Therapeutics, Inc. (ARYX) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2009, ARYx Therapeutics, Inc. reports 27.4M basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

ARYx Therapeutics, Inc.'s basic shares outstanding (27.4M) represents currently issued shares. Diluted shares outstanding (27.4M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.00%.

Shares Outstanding vs. Float (Free Float)

ARYx Therapeutics, Inc.'s float is — (— of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · USD

About shares outstanding & methodology

ARYx Therapeutics, Inc. (ARYX) shares outstanding history from 2003 to 2009. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

ARYx Therapeutics, Inc. shares outstanding for the fiscal year ending December 31, 2009 were 27.4M, a 44.68% increase year-over-year. ARYx Therapeutics, Inc. FY 2009 shares outstanding were 27.4M, a +44.68% increase from FY 2008.

ARYx Therapeutics, Inc. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of — — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.

Frequently asked questions

ARYX shares outstanding · 4 questions

As of December 31, 2009, ARYx Therapeutics, Inc. (ARYX) has approximately 27.4M basic shares outstanding and 27.4M diluted shares outstanding. This represents a +44.68% year-over-year increase from FY 2008 (19.0M). The increase may reflect equity compensation issuances or secondary offerings.

ARYX shares outstandinghow many shares does ARYX haveARYX basic shares 2009ARYX diluted shares

Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · ARYx Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-10